ALB and cancer: When albumin was excluded from the multivariate analysis, only locoregional treatment (HR 8.85, 95% CI 2.85–27.41, P<0.001) and systemic treatment (HR 2.09, 95% CI 1.15–3.81, P=0.016) were independently associated with poorer cancer-specific survival.